ID   184A1
AC   CVCL_3040
AS   CVCL_8222
SY   H184A1
DR   CLO; CLO_0001137
DR   ATCC; CRL-8798
DR   BioSample; SAMN03471210
DR   DepMap; ACH-002319
DR   GEO; GSM350522
DR   GEO; GSM845393
DR   GEO; GSM843436
DR   GEO; GSM1172932
DR   GEO; GSM1172844
DR   IZSLER; BS CL 178
DR   LINCS_HMS; 51088
DR   LINCS_LDP; LCL-2080
DR   PharmacoDB; 184A1_4_2019
DR   Progenetix; CVCL_3040
DR   Wikidata; Q54582476
RX   DOI=10.1007/978-1-4612-0411-4_26;
RX   Patent=US4808532;
RX   PubMed=2702624;
RX   PubMed=3857588;
RX   PubMed=8504475;
RX   PubMed=9671407;
RX   PubMed=12661003;
RX   PubMed=19582160;
RX   PubMed=24176112;
RX   PubMed=25960936;
RX   PubMed=28196595;
RX   PubMed=28889351;
WW   https://hmec.lbl.gov/mreview.htm
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 58.07 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*02:01,02:01; B*18:01,18:01; C*07:01,07:01 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC   Transformant: ChEBI; CHEBI:29865; Benzo[a]pyrene.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Breast; epithelium.
ST   Source(s): ATCC; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D21S11: 29,30
ST   D5S818: 11,13
ST   D7S820: 9,11
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 18,19
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_K049 ! 184
SX   Female
AG   21Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 22
//
RX   DOI=10.1007/978-1-4612-0411-4_26;
RA   Stampfer M.R., Yaswen P., Parry G., Hosoda J.;
RT   "An in vitro human mammary epithelial model system for studies of
RT   differentiation and carcinogenesis.";
RL   (In) Neoplastic transformation in human cell system. Mechanism of carcinogenesis; Rhim J.S., Dritschilo A. (eds.); pp.259-267; Humana Press; New York (1990).
//
RX   Patent=US4808532;
RA   Stampfer M.R.;
RT   "Continuous human cell lines and method of making same.";
RL   Patent number US4808532, 28-Feb-1989.
//
RX   PubMed=2702624; DOI=10.1016/0165-4608(89)90056-3;
RA   Walen K.H., Stampfer M.R.;
RT   "Chromosome analyses of human mammary epithelial cells at stages of
RT   chemical-induced transformation progression to immortality.";
RL   Cancer Genet. Cytogenet. 37:249-261(1989).
//
RX   PubMed=3857588; DOI=10.1073/pnas.82.8.2394;
RA   Stampfer M.R., Bartley J.C.;
RT   "Induction of transformation and continuous cell lines from normal
RT   human mammary epithelial cells after exposure to benzo[a]pyrene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2394-2398(1985).
//
RX   PubMed=8504475; DOI=10.1093/carcin/14.5.833;
RA   Lehman T.A., Modali R., Boukamp P., Stanek J., Bennett W.P.,
RA   Welsh J.A., Metcalf R.A., Stampfer M.R., Fusenig N.E., Rogan E.M.,
RA   Harris C.C.;
RT   "p53 mutations in human immortalized epithelial cell lines.";
RL   Carcinogenesis 14:833-839(1993).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.-F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//